FAIL (the browser should render some flash content, not this).
 

INDUSTRY LEADER

Geneuity and it's parent company MPLN, are industry leaders in advanced molecular level testing. MPLN's impressive history includes:

2007 - Developed abl gene mutation asay to detect Gleevec resistance in CML

2006 - 07 Developed JAK2 V617F qualitatitve and quantitative assays for diagnosis and monitoring of chronic myeloproliferative disorders

2006 - Introduced Luminex technology platform with plans to offer molecular screening of pathogens  for hospital infection control programs

2005 - Began clinical trial testing for new human papillomavirus (HPV) test development

2004 - 05  Developed and introduced quantitative PCR for minimal residual disease (MRD) testing in chronic myelogenous leukemia and acute promyelocytic leukemia (CML, APL)

2004 - Received Molecular Center of Excellence designation by Roche Molecular Systems, Inc.

2003 - Introduced T cell receptor and Immunoglobulin heavy chain gene re-arrangements by PCR

2002 - Introduced Vysis® UroVysion™ Bladder Cancer screen

2002 - Validated Hybrid Capture II HPV assay on SurePath™ Test Pack

2001 - Implemented MPLNet, MPLN’s proprietary laboratory information system customized for molecular diagnostics

2001 - Introduced real time PCR for infectious disease testing

2001 - 510K clearance for Nucleic Acid Transport Media. Developed by MPLN founder Roger Hubbard, PhD and marketed by Medical Packaging, Inc.


2000 - Validated C.trachomatis & N.gonorrhoeae  using ThinPrep PAP Test™ liquid based cytology media.

2000 - Collaborated with Gen-Probe to develop a quantitative assay for bcr/abl  in chronic myelogenous leukemia (CML) by transcription mediated amplification (TMA)

1999 - Introduced Vysis®Her-2 / neu by fluorescence in situ hybridization. Assisted with the validation of sequence-based mutation analyis of HIV.

1999 -Validated Hybrid Capture II assay on ThinPrep PAP Test™

1997 - Introduced technical component only Flow cytometry analysis. Validated HER2/neu breast cancer assay using Oncor, Inc. indirect fluorescence in situ hybridization (FISH) assay

1996 - Participated in an initial study group by invitation from Gen-Probe to develop a novel automated nucleic acid analysis intrument to be named Tigris

1995 - Licensed for PCR by Roche Molecular Systems

1994 - Validated GenProbe M.tuberculosis  by TMA

1993 - Developed and validated a quantitative viral load assay for hepatitis C virus using PCR

1991 - Developed flow cytometry facility for DNA ploidy and leukemia/lymphoma analysis

1990 - Developed T cell receptor, Immunoglobulin heavy and light chain gene rearrangements and bcr/abl rearrangments by Southern blot

1989 - Validated HPV in situ hybridization assay

 
 
  Geneuity © 2009